Israel - Hebräisch - Ministry of Health

rafa laboratories ltd - betahistine hydrochloride 16 mg - tablets - betahistine - meniere`s syndrome. symptomatic treatment of peripheral vertigo.

Israel - Hebräisch - Ministry of Health

"perrigo israel agencies ltd,tayco diagnostics ltd" - כלל האוכלוסיה - התקן להזרקה עצמית תת עורית

Israel - Hebräisch - Ministry of Health

"perrigo israel agencies ltd,tayco diagnostics ltd" - כלל האוכלוסיה - התקן להזרקה עצמית תת עורית

Israel - Hebräisch - Ministry of Health

באייר ישראל בע"מ - כלל האוכלוסיה - התקן להזרקה עצמית תת עורית

Israel - Hebräisch - Ministry of Health

באייר ישראל בע"מ - כלל האוכלוסיה - התקן להזרקה עצמית תת עורית

Israel - Hebräisch - Ministry of Health

איתן ספקים לבתי מרקחת בע"מ - כלל האוכלוסיה - ערכת בדיקה עצמית

Israel - Hebräisch - Ministry of Health

bayer israel ltd - drospirenone; ethinylestradiol as betadex clathrate; levomefolate calcium; levomefolate calcium - טבליות מצופות פילם - levomefolate calcium 0.451 mg; ethinylestradiol as betadex clathrate 0.02 mg; drospirenone 3 mg; levomefolate calcium 0.451 mg - estradiol, combinations

Israel - Hebräisch - Ministry of Health

bayer israel ltd - drospirenone; ethinylestradiol as betadex clathrate; levomefolate calcium; levomefolate calcium - טבליות מצופות פילם - levomefolate calcium 0.451 mg; ethinylestradiol as betadex clathrate 0.03 mg; drospirenone 3 mg; levomefolate calcium 0.451 mg - estradiol, combinations

Israel - Hebräisch - Ministry of Health

roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 5000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative

Israel - Hebräisch - Ministry of Health

roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 10000 iu / 0.6 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with chemotherapy. treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative erythropoietin deficiency* and are receiving anti-tumor therapy. * deficiency is defined as an